S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial.
Conclusion: Adjuvant therapy using S-1 is a cost-effective alternative compared to gemcitabine in patients with postoperative pancreatic cancer from the Chinese societal perspective. PMID: 31597496 [PubMed - as supplied by publisher]
Future Oncology, Ahead of Print.
Authors: Aydın T, Balaban O, Demir L PMID: 31741341 [PubMed - in process]
Pancreatic cystic lesions (PCLs) are commonly encountered, with a prevalence of over 40% in patients undergoing cross-sectional imaging; the incidence increases with age.1 The vast majority are discovered incidentally, are branch duct intraductal papillary mucinous neoplasms (IPMNs), and will never progress to cancer. Despite this, and because the guidelines are controversial and based on little evidence, the management of PCLs continues to create anxiety and frustration for both the patient and the gastroenterologist.
ConclusionsLDP using the “caudo-dorsal artery first approach” is safe and useful for performing a minimally invasive, curative resection for left-sided PC.
In conclusion, microRNA-374 is downregulated in pancreatic cancers and may exhibit therapeutic implications in the pancreatic cancer treatment. PMID: 31737197 [PubMed]
Authors: Brenner DR, Ruan Y, Shaw E, O'Sullivan D, Poirier AE, Heer E, Villeneuve PJ, Walter SD, Friedenreich CM, Smith L, De P Abstract BACKGROUND: Although cancer incidence over time is well documented in Canada, trends by birth cohort and age group are less well known. We analyzed age- and sex-standardized incidence trends in Canada for 16 major cancer sites and all cancers combined. METHODS: We obtained nationally representative population-based cancer incidence data in Canada between 1971 and 2015 from the National Cancer Incidence Reporting System (1969-1992) and the Canadian Cancer Registry (1992-2015). ...
No abstract available
Authors: Brennan GT, Saif MW Abstract Pancreatic enzyme replacement therapy is safe and effective at treating pancreatic exocrine insufficiency. There are multiple causes of pancreatic exocrine insufficiency including chronic pancreatitis, cystic fibrosis and pancreatic cancer. Testing fecal elastase-1 level is useful for the diagnosis of pancreatic exocrine insufficiency. Starting doses of pancreatic enzyme replacement therapy should be at least 30-40,000 IU with each meal and 15-20,000 IU with snacks. pancreatic enzyme replacement therapy should be taken in divided doses throughout meals. Patients who do not resp...